Impact of an Electronic Monitoring Device and Behavioral Feedback on Adherence to Multiple Sclerosis Therapies in Youth: Results of a Randomized Trial
Overview
Rehabilitation Medicine
Authors
Affiliations
Purpose: To report the results of a randomized controlled trial using an electronic monitoring device (EM) plus a motivational interviewing (MI) intervention to enhance adherence to disease-modifying therapies (DMT) in pediatric MS.
Methods: Fifty-two youth with MS (16.03 ± 2.2 years) were randomized to receive either MI (n = 25) (target intervention) or a MS medication video (n = 27) (attention control). Primary endpoint was change in adherence. Secondary outcomes included changes in quality of life, well-being and self-efficacy. Random effects modeling and Cohen's effect size computation evaluated intervention impact.
Results: Longitudinal random effect models revealed that the MI group decreased their EM adherence (GroupxTime interaction = -0.19), while increasing frequency of parental DMT reminder (26.01)/administration (11.69). We found decreased EM use in the MI group at 6 months (Cohen's d = -0.61), but increased pharmacy refill adherence (d = 0.23). Parental reminders about medication increased in MI subjects vs controls (d = 0.59 at 3 months; d = 0.70 at 6 months). We found increases in self-reported adherence (d = 0.21) at 3 but not 6 months, fewer barriers to adherence at three (d = -0.58) and six months (d = -0.31), better physical (d = 0.23 at 3 months; d = 0.45 at 6 months), emotional (d = 0.25 at 3 months) and self-efficacy function (d = 0.55 at 3 months; 0.48 at 6 months), but worse well-being, including self-acceptance (d = -0.53 at 6 months) and environmental mastery (d = -0.42 at 3 and 6 months) in intervention as compared to control patients.
Conclusions: Participants receiving MI + EM experienced worsening on objective measures of adherence and increased parental involvement, but improved on some self- and parent-reported measures. MI participants reported improvements in quality of life and self-efficacy, but worsened well-being.
Suntornlohanakul R, Yeh E Paediatr Drugs. 2024; 27(2):161-179.
PMID: 39724509 DOI: 10.1007/s40272-024-00675-1.
The State of the Art of Pediatric Multiple Sclerosis.
Teleanu R, Niculescu A, Vladacenco O, Roza E, Perjoc R, Teleanu D Int J Mol Sci. 2023; 24(9).
PMID: 37175954 PMC: 10179691. DOI: 10.3390/ijms24098251.
The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis.
Greene N, Araujo L, Campos C, Dalglish H, Gibbs S, Yermilov I J Health Econ Outcomes Res. 2022; 9(2):103-114.
PMID: 36348724 PMC: 9584745. DOI: 10.36469/001c.37992.
Chan A, Foot H, Pearce C, Horne R, Foster J, Harrison J PLoS One. 2022; 17(3):e0265715.
PMID: 35312704 PMC: 8936478. DOI: 10.1371/journal.pone.0265715.
Mroskova S, Klimova E, Majernikova L, Tkacova L Int J Environ Res Public Health. 2021; 18(16).
PMID: 34444393 PMC: 8392317. DOI: 10.3390/ijerph18168645.